COGNITION THERAPEUTICS INC Stock Price, News & Analysis

Cognition Therapeutics (NASDAQ: CGTX) showcased a poster at the ARVO meeting, highlighting that sigma-2 receptor modulators can restore the normal functioning of retinal pigment epithelial (RPE) cells impaired by dry age-related macular degeneration (AMD).

CT1812, Cognition's lead candidate, demonstrated the ability to rescue vital functions of RPE cells in in vitro models. The company plans to initiate a Phase 2 clinical trial with CT1812 in patients with dry AMD in late 2022. Dry AMD affects around 190 million individuals globally, making it a significant health concern.

Cognition Therapeutics (NASDAQ: CGTX) announced its participation in the ARVO 2022 conference, showcasing preclinical results on sigma-2 receptor modulators that protect retinal pigmented epithelium (RPE) cells. Their lead candidate, CT1812, aims to address dry age-related macular degeneration (AMD) and a Phase 2 clinical study is planned. Dry AMD affects approximately 190 million globally, causing significant vision loss. The poster presentation is scheduled for May 3, 2022, highlighting how these modulators can normalize disrupted homeostatic processes in RPE cells.

Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that its management will participate in a virtual fireside chat at the B. Riley Securities’ Neuro & Ophthalmology Conference on April 27-28, 2022. The discussion will focus on advancements in their clinical programs targeting age-related diseases affecting the central nervous system and retina, particularly their lead candidate, CT1812. A webcast will be available for viewers, outlining the company's ongoing research and development efforts in Alzheimer’s disease and other conditions.

Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced participation in Needham & Company's 21st Annual Virtual Healthcare Conference from April 11-14, 2022. CEO Lisa Ricciardi will provide a corporate update on April 11, 2022, from 3:00 to 3:40 p.m. ET. A live and archived webcast will be available on the company's investor website. The company focuses on developing innovative drugs targeting age-related degenerative diseases affecting the central nervous system and retina, leveraging expertise in sigma-2 receptor mechanisms.

Cognition Therapeutics (NASDAQ: CGTX) reported a solid financial position after raising $52 million through an upsized IPO and securing $169 million in grant funding. The company is advancing its clinical pipeline for Alzheimer’s disease and dementia with Lewy bodies (DLB), with plans for Phase 2 studies in dry AMD and early-stage Alzheimer’s expected to begin in H2 2022. Despite a net loss of $11.7 million in 2021, Cognition's robust cash reserves of $54.7 million are projected to sustain operations through mid-2023.

Cognition Therapeutics, Inc. (Nasdaq: CGTX) plans to announce its fourth quarter and full year financial results for 2021 on March 30, 2022, before market open. Following this release, the company will host a conference call at 8:00 a.m. ET to discuss the results and provide a business update. Participants can join via telephone or an audio webcast accessible on the company’s website. Cognition focuses on developing innovative therapeutics targeting age-related degenerative diseases.

Cognition Therapeutics (CGTX) is showcasing findings from its clinical development program for CT1812, a sigma-2 receptor modulator targeting Alzheimer's disease, at the AD/PD™ 2022 conference in Barcelona from March 15-20, 2022. Results from the Phase 1b SNAP study indicate significant beta amyloid oligomer displacement into cerebrospinal fluid after CT1812 administration, contrasting with placebo results. Additionally, preliminary findings from the Phase 2 SHINE study highlight potential pharmacodynamic biomarkers linked to Alzheimer's treatment. Full SNAP results will be published in a peer-reviewed journal later this year.

Cognition Therapeutics (Nasdaq: CGTX) announces CEO Lisa Ricciardi's participation in two healthcare conferences. The Oppenheimer 32nd Annual Healthcare Conference will take place on March 16, 2022, at 4:00 p.m. ET, with a live webcast available for 90 days. The Sachs Neuroscience Innovation Forum, focusing on Alzheimer's and dementia, is scheduled for March 22, 2022, at 10:00 a.m. ET, also offering live and on-demand access for registered participants. One-on-one meetings with Ricciardi can be scheduled through event representatives.

Cognition Therapeutics (Nasdaq: CGTX) announced that Anthony Caggiano, M.D., Ph.D., will participate in the BIO CEO & Investor Conference on February 15, 2022, discussing neurodegenerative therapeutics. This panel aims to explore innovative partnerships in the field following a significant investment surge in neuroscience in 2020. Dr. Caggiano emphasized the renewed interest in therapies targeting biological pathways in neurological diseases, highlighting their sigma-2 receptor modulators. The event will be webcasted for registered attendees.